Image de couverture de livre

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteur principal:	Iskandar Idris
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Diabetes, Obesity and Metabolism Now
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
par: Iskandar Idris
Publié: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
par: Iskandar Idris
Publié: (2024)

Epigenetic changes shown to cause type 2 diabetes
par: Iskandar Idris
Publié: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
par: Iskandar Idris
Publié: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
par: Iskandar Idris
Publié: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
par: Iskandar Idris
Publié: (2024)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
par: Iskandar Idris
Publié: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
par: Iskandar Idris
Publié: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
par: Iskandar Idris
Publié: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
par: Iskandar Idris
Publié: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
par: Iskandar Idris
Publié: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
par: Iskandar Idris
Publié: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
par: Iskandar Idris
Publié: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
par: Iskandar Idris
Publié: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
par: Iskandar Idris
Publié: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
par: Iskandar Idris
Publié: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
par: Iskandar Idris
Publié: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
par: Iskandar Idris
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Comments on ‘Propensity score matching methodology in Riley et al.'s study on type 2 diabetes and obstructive sleep apnoea’
par: Shao‐Wei Lo, et autres
Publié: (2025)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
par: Iskandar Idris, et autres
Publié: (2025)

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
par: Kathryn Giblin, et autres
Publié: (2025)

Comparative effectiveness of continuous positive airway pressure and glucagon‐like peptide‐1 receptor agonists in obstructive sleep apnea: A network meta‐analysis of randomised trials
par: Gaspar R. Chiappa, et autres
Publié: (2026)

The effect of altered sleep timing on glycaemic outcomes: Systematic review of human intervention studies
par: Romy Slebe, et autres
Publié: (2024)

Obstructive sleep apnea is associated with greater MASH and significant fibrosis severity in patients with obesity: A prospective clinicopathological study
par: Jia Feng, et autres
Publié: (2026)

Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide
par: Man Sun, et autres
Publié: (2026)

Obstructive sleep apnea is associated with impaired insulin clearance and hepatic insulin sensitivity in paediatric obesity
par: Giuseppina Rosaria Umano, et autres
Publié: (2025)

Tirzepatide in the NHS : The known unknowns of treating obesity at a national scale
par: Ashley Kieran Clift, et autres
Publié: (2025)

Spillover effects of a nudge‐based dietary intervention on physical activity and sleep among adults with type 2 diabetes: Evidence from a randomised controlled trial
par: Xiaojing Guo, et autres
Publié: (2026)

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
par: Andreea Ciudin, et autres
Publié: (2026)

The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China
par: Sihua Wang, et autres
Publié: (2025)

Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’
par: Chih‐Yuan Wang
Publié: (2026)

Interpreting Lean Mass Changes During Tirzepatide‐Induced Weight Loss: Beyond Quantitative Metrics
par: Tuba Uyanık
Publié: (2026)